Videos

Neurology News Network for the week of September 28, 2018.

Potential risk factors may identify those at risk for AD and similar disorders as early as adolescence.

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.

The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.

Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.

Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

Silberstein spoke about the new mechanism-based treatments that are revolutionary in changing the treatment landscape of migraine.

Neurology News Network for the week of September 22, 2018.

For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.

Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.

The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.

A meta-analysis of 16 studies looked at the association between apathy in older individuals with and without incident dementia.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.

Neurology News Network for the week of September 15, 2018.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.

The MS expert discussed the field's recent foray into treating progressive forms of the disease and what is in development.

While there isn’t one agent Coyle believes is held above the rest, she noted that the oral therapies have become popular due to ease of administration.

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke about the relationship between primary care and specialists.

Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.

The Saunders Family Professor of Neurology and the director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center discussed the need for biomarkers in MS.

How did erenumab's approval by the FDA change the landscape of migraine treatment?

After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.